Pharma: Page 41
-
Q&A
Exscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started
The company’s CEO on the road ahead for AI capabilities in pharma.
By Meagan Parrish • March 4, 2022 -
Podcast
Woman of the Week: Lyndra Therapeutics' CEO Dr. Trish Hurter
With Lyndra's ultra-long-acting therapies, Hurter and the company are aiming to reinvent medicines.
By Taren Grom • March 2, 2022 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
The 2022 PharmaVoice 100 — new look, same drive for excellence
Some of the industry’s biggest names have been on our list of honorees. Now it’s time to find this year’s inspiring leaders.
By Taren Grom • Feb. 28, 2022 -
Sponsored by Magnolia
Reaching the rare: How can we best support and engage with the rare disease community during the pandemic?
How can we better understand the challenges defining the pandemic journey of a rare disease patient?
Feb. 28, 2022 -
Profile
Guadalupe Hayes-Mota's 'recipe' for tackling pharma's supply chain issues
A quest to expand access to medical treatment globally led to a new career path when Guadalupe Hayes-Mota left his biotech leadership roles to start his own company.
By Robin Robinson • Feb. 25, 2022 -
Podcast
Woman of the Week: Sumitovant's Chief Business Development and Commercial Officer Adele Gulfo
Adele Gulfo, chief business development and commercial officer at Sumitovant Biopharma, is leaning into her decades of experience to bring a future-focused approach to drug development.
By Taren Grom • Feb. 23, 2022 -
Eisai's mission to shake off Aduhelm's shadow and bring another AD drug to market
The company's senior VP of clinical research on how they're building off the science of Aduhelm to develop better Alzheimer's treatments.
By Kelly Bilodeau • Feb. 23, 2022 -
Podcast
Woman of the Week: Organon's Chief Commercial Officer Susanne Fiedler
Susi Fiedler, chief commercial officer, was instrumental in the spinout of Organon as a standalone company focused on a broad range of women’s health issues.
By Taren Grom • Feb. 16, 2022 -
Q&A
Winning buy-in from early stage biotech investors
The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.
By Taren Grom • Feb. 11, 2022 -
Opinion
Industry executives on the milestone moments shaping pharma's future
Scientific, technological, and communication changes that are making a permanent impact on the industry.
By Taren Grom • Feb. 9, 2022 -
Q&A
Innovation vs. invention
IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.
By Taren Grom • Feb. 9, 2022 -
Q&A
Saniona's CEO on why it takes a village to develop treatments for a rare disease
Saniona built its village by first hiring a head of patient advocacy.
By Kim Ribbink • Feb. 8, 2022 -
Q&A
Why 23andMe's first solo clinical trial is a big deal
It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come.
By Taren Grom • Feb. 7, 2022 -
Home is where the trial is
Facing pandemic disruptions, smaller biotechs are discovering the benefits and challenges of turning to decentralized clinical trials.
By Kelly Bilodeau • Feb. 7, 2022 -
Retrieved from MaxPixel.
Pharma's pain points with AI
Looking beyond the buzz and at the challenges associated with AI.
By Meagan Parrish • Feb. 7, 2022 -
Ferring Pharmaceuticals president discusses the need for more funding in women's health research
Read why women's healthcare funding is such a challenge.
By Robin Robinson • Feb. 4, 2022 -
Retrieved from Google image.Opinion
Industry executives predict the next 'blue oceans' in pharma
Where life science leaders see breakthroughs happening in the industry.
By Taren Grom • Feb. 4, 2022 -
Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics
With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.
By Robin Robinson • Feb. 3, 2022 -
Podcast
Woman of the Week: Syneos Health's president of commercial solutions, Michelle Keefe
How Michelle Keefe, president, commercial solutions at Syneos Health, steered her team into a rapid pivot during the pandemic.
By Taren Grom • Feb. 2, 2022 -
Opinion
Talent acquisition stays top of mind for pharma execs
From creating flexible work environments to looking outside the industry for new talent, pharma execs are shifting strategies to keep their teams afloat.
By Taren Grom • Feb. 1, 2022 -
Retrieved from Rare Disease.org.Q&A
For the CEO of Travere, running a rare disease company is personal
To kick off Rare Disease month, we interview the CEO of Travere Therapeutics
By Kim Ribbink • Feb. 1, 2022 -
Opinion
Biopharma's R&D leaders on how technology can accelerate drug development
How emerging digital tools are providing enhanced clinical insights and improved trial results.
By Taren Grom • Jan. 27, 2022 -
Q&A
Sanofi's chief scientist on why 'this is the moment' for AI in Big Pharma
How a $5.2 billion AI investment is enabling the French pharma to accelerate drug development.
By Meagan Parrish • Jan. 27, 2022 -
Q&A
With its wealth of patient data, Walgreens is looking to disrupt the clinical trial space
How the mega-pharmacy’s clinical trials officer is looking to capitalize on its deep well of patient data to create an interconnected healthcare system of the future.
By Taren Grom • Jan. 26, 2022 -
Podcast
Woman of the Week: Janssen's Dr. Sylvie Laquerre
Why following the science is crucial when bringing new compounds to market.
By Taren Grom • Jan. 26, 2022